pharmaphorum

JULY 26, 2022

The looming competition piles further pressure on Biogen, whose MS franchise is already beset by generic competition to oral therapy Tecfidera (dimethyl glutamate), while its attempt to build a market for Alzheimer’s therapy Aduhelm (aducanumab) has ended in failure.

Competition 52

Competition Side effects Marketing Sales 52

LEVO Health

JULY 15, 2024

billion by 2027. This growth presents a significant opportunity for healthcare organizations and businesses, but it also means the market is becoming increasingly saturated. Take Your GLP-1 Program to the Next Level The GLP-1 market presents a lucrative opportunity for healthcare organizations and businesses.

Marketing 52

Marketing Side effects Education Medical 52

Medico Reach

FEBRUARY 8, 2023

Hence, looking closer at the future trends in pharma industry only makes sense for businesses to stay afloat in the healthcare market. Here are some more applications of AI in healthcare and pharma Medicines discovery and design can improve drastically. billion by 2027. billion in big data analytics.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

With the global atrial fibrillation market at $6 billion today, that rate of growth would push it to $12 billion by mid-2027, if not sooner, with PFA accounting for about 70% of the market. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up.

Marketing 52

Marketing Competition FDA Electronics 52

European Pharmaceutical Review

FEBRUARY 7, 2023

However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors.

Medical 117

Medical Government Marketing Medicine 117

Evolve Your Success

OCTOBER 31, 2023

Tune in and discover how one individual’s dedication can truly make a difference in the world of healthcare. It’s very competitive. By 2027, they are projected to be about $10 billion. Medical sale is a lot more volatile. I made it all the way to my very last interview. It was me and one other guy.

Engineering 52

Engineering Sales Medical sales Medical 52

Pharmaceutical Technology

NOVEMBER 30, 2022

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. In the US, obesity care is estimated at to cost $147 billion in healthcare spending annually.

Medical 98

Medical Manufacturing Insurance Side effects 98

Pharmaceutical Technology

FEBRUARY 6, 2023

A Pliant spokesperson said, “This successful transaction, along with existing cash, cash equivalents, loan agreement and short-term investments, provides for operations to be funded to mid-2027, a year past the expected IPF Phase 2b clinical trial readout.” The company said a Phase IIb trial initiation should be expected in mid-2023.

Marketing 59

Marketing Pharmaceutical FDA Prospecting 59

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. In highly competitive categories like diabetes, net price could be half of the list price. Although the initial set of drugs included for negotiations was limited to ten, the scope of this program will expand over time.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52